We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Merck's Keytruda

News List

Merck's Keytruda shores up head and neck case with first-line trial win fiercepharma
July 27, 2018
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals fiercepharma
September 11, 2017
MADRID, Spain—Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting.
Despite benefits, Merck's Keytruda falls short at NICE in urothelial carcinoma americanpharmaceuticalreview
August 07, 2017
In an initial review, cost watchdogs in England turned away Merck's Keytruda to treat urothelial carcinoma.